Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

Tildrakizumab for Moderate-to-Severe Plaque Psoriasis Skin Therapy Lett. 2019 Nov;24(6):1-4 Authors: Mui UN, Patel RR, Vangipuram R, Tyring SK Abstract Psoriasis is an immune-mediated inflammatory skin condition associated with many comorbidities and poor quality of life. The pathogenesis of psoriasis is complex and involves numerous proinflammatory cytokines. Many biologic therapies have been developed to block the action of these proinflammatory molecules, including inhibitors of tumor necrosis factor (TNF), interleukin (IL)-17, IL-12, and IL-23. IL-23 is composed of two subunits, p19 and p40. The p40 subunit is shared with IL-12, and inhibitors of the p40 subunit can block both IL-12 and IL-23 signaling. Recent advances in the understanding of psoriasis, however, have shown IL-23 to be more important than IL-12 in the pathogenesis of psoriasis. This has led to the development of IL-23p19 antagonists, the newest class of biologics for psoriasis. Here, we will discuss the safety and efficacy of tildrakizumab, a monoclonal antibody targeting IL-23p19. PMID: 31801012 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research
More News: Dermatology | Psoriasis | Skin